The 12th International Conference on HHV-6 & HHV-7 will be held between March 25-27, 2025 in Himeji, Japan.
Day 1: Tuesday March 25th
Yasuko Mori, MD, PhD
Professor
Division of Clinical Virology
Kobe University Graduate School of Medicine
Japan
Keynote: HHV-6 genes & proteins
With over 80 papers on HHV-6, Professor Mori has conducted pioneering research into the viral entry properties of HHV-6, including the discovery of the specific cellular receptor for HHV-6B entry.
Benedikt Kaufer, PhD
Professor and Managing Director
Institute of Virology
Free University
Germany
New findings on HHV-6 chromosomal integration
Professor Kaufer studies viral integration and tumorigenesis and has made significant contributions to the understanding of inherited chromosomally integrated HHV-6 and demonstrated that HHV-6A could be excised from genomes using CRISPR/Cas9.
Louis Flamand, PhD
Professor
Microbiology-Immunology
Laval University
Canada
The biology and consequences of HHV-6 integration
Dr. Flamand is a top expert on inherited chromosomally integrated HHV-6 and studies both the underlying cellular mechanisms as well as the biological consequences of the condition.
Tetsushi Yoshikawa, MD, PhD
Professor
Fujita Health University School of Medicine
Japan
Professor Yoshikawa is one of the world’s leading experts on HHV-6, with over 150 publications, including the role of HHV-6B in the pathogenesis of MTLE and the analysis of iciHHV6 in the Japanese population.
Ruth Jarrett, MBCHB
Professor of Molecular Biology
Center for Virus Research
University of Glasgow
Scotland
Epidemiology and clinical disease associations of iciHHV-6 in the UK
Professor Jarrett recently completed a major study on the clinical impact of iciHHV-6 using the UK Biobank. She has studied the possible role of viruses including HHV-6 in the pathogenesis of Hodgkin lymphoma.
Day 2: Wednesday March 26th
Danielle Zerr, MD
Professor and Division Chief
Pediatric Infectious Diseases
University of Washington and Seattle Children’s Hospital
USA
Dr. Zerr was the first to associate delirium and cognitive decline with HHV-6B reactivation post hematopoietic stem cell transplantation and has led a number of meta-analyses demonstrating the adverse consequences of HHV-6B reactivation.
Masao Ogata, MD, PhD
Professor
Department of Hematology
Blood Transfusion Center
Oita University Faculty of Medicine
Japan
Professor Ogata has authored key papers on the use of foscarnet for prophylactic and pre-emptive therapies for HHV-6 encephalitis. He was the lead author on the clinical practice recommendations of the Japan Society for Hematopoietic Cell Transplantation.
Genovefa Papanicolaou, MD
Professor
Department of Medicine
Memorial Sloan Kettering Cancer Center
Department of Medicine
Weill Cornell Medical College
Cornell University
USA
HHV-6 infection in HCT
Dr. Papanicolaou is the current Chair of the Infectious Disease Special Interest Group of the American Society for Transplantation and Cellular Therapy, focusing on viral infections after stem cell transplantation.
Hideo Asada, MD, PHD
Professor
Department of Dermatology
Nara Medical University School of Medicine
Japan
Professor Asada is an expert on HHV-6 and drug-induced hypersensitivity syndrome (DIHS). He has published over 15 papers relating to HHV-6 & 7 and hypersensitivity reactions.
Day 3: Thursday March 27th
Steven Jacobson, PHD
Senior Investigator, Viral Immunology
National Institute of Neurological Disorders and Stroke
USA
Dr. Jacobson has been studying HHV-6 and other persistent viral infections in central nervous system for over 30 years, co-authoring over 65 publications. He found elevated levels of HHV-6B in biopsy tissue from MTLE patients and demonstrated that HHV-6 triggers neuroinflammation in a non-human primate model of multiple sclerosis.
Michael Boeckh, MD, PhD
Professor of Medicine
Fred Hutch Cancer Research Center
Vaccine and Infectious Disease
University of Washington
USA
The way forward for HHV-6 research and antiviral treatment
An author on over 30 papers relating to HHV-6, Professor Boeckh he was one of the first to identify delayed engraftment, CNS dysfunction, and increased aGVHD and all-cause mortality due to HHV-6 reactivation.